1. Home
  2. Detail

@quynhmetruoi: #giadungtienich #quangcao #duoctaitro

Quỳnh Mét Rưỡi
Quỳnh Mét Rưỡi
Open In TikTok:
Region: VN
Friday 28 August 2026 11:19:09 GMT
417
1
0
2

Music

Download

No Watermark .mp4 (8.44MB) No Watermark(HD) .mp4 (8.44MB) Watermark .mp4 (8.82MB) Music .mp3

Comments

There are no more comments for this video.
To see more videos from user @quynhmetruoi, please go to the Tikwm homepage.

Other Videos

Ta nói nó thơm khủng khíp luôn á #adolphvietnam #tocthom
Ta nói nó thơm khủng khíp luôn á #adolphvietnam #tocthom
🇪🇹🇸🇦✍️✍️✍️
🇪🇹🇸🇦✍️✍️✍️


kalah lagi, terima lagi #lestykejora #rizkybillar #leslar #lestylovers #fyppppppppppppppppppppppp @Lesti Kejora @rizkybilar___
kalah lagi, terima lagi #lestykejora #rizkybillar #leslar #lestylovers #fyppppppppppppppppppppppp @Lesti Kejora @rizkybilar___
Anunge ewa hoyan නැතුව thamange wedak blgnna 🫵😊😂 #foryour #fypシ゚viral #quotes #trending #viralpalayankomekawath🙂😞
Anunge ewa hoyan නැතුව thamange wedak blgnna 🫵😊😂 #foryour #fypシ゚viral #quotes #trending #viralpalayankomekawath🙂😞
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly

About

Legal